STATEMENT OF NEED
Prostate cancer is the most common tumor type in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years.
Urologists, oncologists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).
Upon completion of this activity, participants should be able to:
- Evaluate efficacy and safety data on novel therapeutic regimens for metastatic CRPC
- Describe considerations in determining optimal sequences of therapy for patients with metastatic CRPC
- Assess predictive and prognostic markers to refine treatment planning for individual patients with metastatic CRPC
Oliver Sartor, MD (Chairperson)
C.E. and Bernadine Laborde Professor of Cancer Research
Tulane University School of Medicine
Robert Dreicer, MD, MS, MACP, FASCO
Professor of Medicine and Urology
University of Virginia School of Medicine
Susan Slovin, MD, PhD
Professor of Medicine
Weill-Cornell Medical College
L. Michael Glodé, MD, FACP
Professor, Robert Rifkin Chair for Prostate Cancer Research
University of Colorado School of Medicine
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Feinberg School of Medicine
Dicken S. Ko, MD
Associate Professor of Surgery
Harvard Medical School
Brian D. Robinson, MD
Co-Chief of Urologic Pathology
Weill-Cornell Medical College
There is no fee to participate in or claim CME credit for this activity.
Please note that the University of Cincinnati and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
A. Oliver Sartor, MD discoloses that he has served as a consultant for AstraZeneca, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, EMD Serono, Johnson & Johnson, Oncogenex, Pfizer, Sanofi-Aventis, and Tokai. He has received grants/research support from Bayer, Endocyte, Innocrin, Johnson & Johnson, and Sanofi-Aventis.
Robert Dreicer, MD, MS, MACP, FASCO disloses that he has served on the advisory board for Asana, Astellas, AstraZeneca, Eisai, EMD Serono, Janssen, Medivation, Orion, Pfizer, and Sanofi-Genzyme.
Susan Slovin, MD, PhD has no relevant financial relationships to disclose.
L. Michael Glodé, MD, FACP discloses that he has served as a review panel member for Janssen.
Alicia K. Morgans, MD, MPH discloses that she has served on the advisory board for AstraZeneca, Genentech, and Janssen.
Brian D. Robinson, MD discloses that he has served as a consultant for Bristol-Myers Squibb and Progenics Pharmaceutical, Inc.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. and Genzyme.